Clinical Trial Update: CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating CPX-351 in combination with gemtuzumab ozogamicin for newly diagnosed Acute Myeloid Leukemia; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING